C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

NCT ID: NCT00125541

Last Updated: 2009-05-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2008-05-31

Brief Summary

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.

Detailed Description

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.

Conditions

Angioedema

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

C1 inhibitor concentrate (C1-esteraseremmer-N)

every 5-7 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Established diagnosis of hereditary angioedema type I or II: markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4.
• Patients already using C1 inhibitor concentrate for prophylaxis of angioedema attacks.
• Age ≥ 16 years
• Signed informed consent by patient and patient's legal representative if under 18 years old

• Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4.
• Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life.
• Age ≥ 16 years
• Patient already using C1 inhibitor concentrate for prophylaxis of angioedema attacks
• Signed informed consent by patient and patient's legal representative if under 18 years old

Exclusion Criteria

• Use of angioedema prophylactic medication during the study, other than C1-esteraseremmer-N.
• Change in oral contraceptives starting from the last two months before the start of the trial until the end of the study period.
• Presence of clinically relevant C1 inhibitor auto antibodies
• Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than in part A of this protocol.
• Usage of heparin starting from the last two days prior to the study until the end of the study period.
• B-cell malignancy
• Pregnancy or lactation
• History of allergic reaction to C1 inhibitor concentrate or other blood products

• Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study
• Usage of heparin within the last two days prior to the study
• Pregnancy or lactation
• History of allergic reaction to C1 inhibitor concentrate or other blood products

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prothya Biosolutions

INDUSTRY

Sponsor Role: lead

Responsible Party

Sanquin

Principal Investigators

M. M. Levi, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Academic Medical Centre Amsterdam

Locations

Academic Medical Centre

Amsterdam, , Netherlands

Countries

Netherlands

Other Identifiers

KB2003.01C

Identifier Type: -

Identifier Source: org_study_id